Achieve Life Sciences (NASDAQ:ACHV) Announces Quarterly Earnings Results

Achieve Life Sciences (NASDAQ:ACHV) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06), Zacks reports.

Achieve Life Sciences Price Performance

Achieve Life Sciences stock opened at $3.06 on Tuesday. The firm has a market cap of $105.23 million, a PE ratio of -2.71 and a beta of 1.67. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.78 and a quick ratio of 6.78. The stock’s fifty day moving average price is $3.23 and its two-hundred day moving average price is $4.06. Achieve Life Sciences has a one year low of $2.82 and a one year high of $5.59.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Rodman & Renshaw initiated coverage on Achieve Life Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $12.00 price target for the company. RODMAN&RENSHAW raised Achieve Life Sciences to a “strong-buy” rating in a report on Thursday, November 14th. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $15.75.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.